$0.90
1.63%
Nasdaq, Jul 03, 10:54 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.90
+0.27 42.56% 1M
+0.11 14.25% 6M
+0.16 22.00% YTD
-0.76 45.72% 1Y
-1.04 53.56% 3Y
-1.04 53.56% 5Y
-7.26 88.96% 10Y
-32.98 97.34% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
-0.01 1.63%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Basic
Market capitalization
$327.2m
Enterprise Value
$233.1m
Net debt
positive
Cash
$194.8m
Shares outstanding
363.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.5 | 18.8
EV/Sales
7.5 | 13.4
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
48.9%
Return on Equity
-137.3%
ROCE
-94.9%
ROIC
-
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$31.2m | $17.4m
EBITDA
$-176.9m | $-123.1m
EBIT
$-177.5m | $-147.4m
Net Income
$-177.3m | $-145.7m
Free Cash Flow
$-167.4m
Growth (TTM | estimate)
Revenue
1,239.5% | -44.1%
EBITDA
4.5% | 37.4%
EBIT
4.5%
Net Income
8.4% | 27.3%
Free Cash Flow
9.8%
Margin (TTM | estimate)
Gross
98.0%
EBITDA
-566.7% | -708.7%
EBIT
-568.6%
Net
-568.0% | -838.9%
Free Cash Flow
-536.4%
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
28.9%
Employees
103
Rev per Employee
$300.0k
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,966 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
1,239% 1,239%
100%
- Direct Costs 0.62 0.62
520% 520%
2%
31 31
1,272% 1,272%
98%
- Selling and Administrative Expenses 123 123
3% 3%
393%
- Research and Development Expense 85 85
39% 39%
274%
-177 -177
5% 5%
-567%
- Depreciation and Amortization 0.57 0.57
5% 5%
2%
EBIT (Operating Income) EBIT -177 -177
5% 5%
-569%
Net Profit -177 -177
8% 8%
-568%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) announced tha...
Neutral
GlobeNewsWire
18 days ago
THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) --   Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the compan...
Neutral
GlobeNewsWire
about one month ago
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's ...
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today